Premium
Letter: should anti‐viral therapy be recommended for individuals chronically infected with hepatitis B virus and at low risk of hepatocellular carcinoma? Authors’ reply
Author(s) -
Lin D.,
Yang H.I.,
Hoang J.,
Nguyen M. H.
Publication year - 2017
Publication title -
alimentary pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.308
H-Index - 177
eISSN - 1365-2036
pISSN - 0269-2813
DOI - 10.1111/apt.13849
Subject(s) - medicine , hepatocellular carcinoma , virology , zhàng , hepatitis b virus , antiviral therapy , virus , viral therapy , gastroenterology , chronic hepatitis , covid-19 , disease , political science , law , infectious disease (medical specialty) , china
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom